PSA: Which Tests to Order Alongside for a Complete Prostate and Hormone Picture

What PSA Actually Measures and Why It Is Not Enough Alone

Prostate-specific antigen is a serine protease produced by both normal and malignant prostate epithelial cells. Its job is to liquefy semen. A blood test captures the small fraction that leaks into circulation, and that number rises with prostate volume, inflammation, infection, and cancer. The problem is specificity: PSA cannot distinguish between these causes on its own.

The landmark Prostate Cancer Prevention Trial (PCPT) demonstrated that 15.2% of men with a PSA below 4.0 ng/mL still harbored biopsy-detectable prostate cancer (Thompson et al., NEJM 2004). That single finding ended the era of treating 4.0 ng/mL as a reliable binary cutoff. A PSA result is a starting point. The tests you order alongside it determine whether the next step is reassurance, surveillance, or referral.

The USPSTF 2018 recommendation upgraded PSA-based screening for men aged 55, 69 to a grade C (individual decision), explicitly noting that shared decision-making should weigh baseline PSA, family history, and race. For men on testosterone replacement therapy (TRT), the Endocrine Society's 2018 clinical practice guideline recommends PSA measurement at baseline, at 3 to 6 months, and annually thereafter, with referral to urology if PSA exceeds 4.0 ng/mL or if PSA velocity exceeds 1.4 ng/mL per year (Bhasin et al., JCEM 2018).

Free PSA and Percent-Free PSA: The First Add-On

When total PSA falls in the 4 to 10 ng/mL "gray zone," free PSA percentage is the single most useful reflex test. Cancer cells produce PSA that binds more readily to serum proteins, so a low percentage of free (unbound) PSA suggests malignancy.

A multi-center study of 773 men found that using a 25% free PSA cutoff detected 95% of cancers while avoiding 20% of unnecessary biopsies (Catalona et al., JAMA 1998). The ratio works in a straightforward way: values above 25% point toward benign prostatic hyperplasia (BPH), while values below 10% raise significant concern for cancer. Between 10% and 25% is an intermediate zone where additional testing (PHI, 4Kscore, or MRI) adds the most value.

Order free PSA at the same blood draw as total PSA whenever possible. The specimen must be processed within 3 hours because free PSA degrades faster than bound PSA at room temperature. A delayed spin can artificially lower the free-to-total ratio and trigger unnecessary alarm.

Testosterone Panel: Total, Free, and SHBG

PSA and testosterone are biochemically linked. Testosterone is converted to dihydrotestosterone (DHT) in prostate tissue, and DHT drives PSA production. Any man being evaluated for low testosterone needs a baseline PSA, and any man on TRT needs serial PSA monitoring.

The minimum testosterone panel to pair with PSA includes total testosterone (morning draw, fasting preferred), free testosterone (calculated or equilibrium dialysis), and sex hormone-binding globulin (SHBG). SHBG rises with age, liver disease, and hyperthyroidism, and it binds testosterone tightly. A man with a total testosterone of 450 ng/dL but an SHBG of 80 nmol/L may have a free testosterone well below the reference range, which changes the clinical picture entirely.

The Endocrine Society guideline defines testosterone deficiency as a total testosterone consistently below 300 ng/dL measured by a reliable assay on at least two morning samples (Bhasin et al., JCEM 2018). When initiating TRT, PSA should be rechecked at 3 to 6 months. A meta-analysis of 18 randomized controlled trials (N=5,091) found that testosterone therapy raised PSA by a mean of 0.47 ng/mL over 12 months, with no statistically significant increase in prostate cancer incidence compared to placebo (Boyle et al., BMJ Open 2016).

Complete Blood Count: Why It Belongs on Every PSA Order

A CBC is not a prostate test. It earns its place on the paired-test list for two reasons: polycythemia monitoring during TRT and detection of systemic inflammation that can falsify PSA readings.

Testosterone stimulates erythropoiesis. The Testosterone Trials (TTrials, N=790) showed that hematocrit increased by a mean of 2.6 percentage points in men receiving transdermal testosterone for 12 months (Snyder et al., NEJM 2016). A hematocrit above 54% requires dose reduction or temporary cessation per most clinical guidelines, because the thromboembolic risk rises sharply. Checking CBC at the same draw as PSA creates no extra cost or patient burden, and it prevents the common error of ordering TRT follow-up labs piecemeal across multiple visits.

Elevated white blood cell counts or a left shift can signal prostatitis or urinary tract infection, both of which raise PSA independently of cancer. Identifying infection before acting on an elevated PSA avoids unnecessary biopsies. The standard practice: treat the infection, wait 4 to 6 weeks (roughly two PSA half-lives), then recheck.

Comprehensive Metabolic Panel and Lipid Panel

A CMP paired with PSA serves metabolic surveillance. Men being evaluated for testosterone deficiency frequently have comorbidities (metabolic syndrome, type 2 diabetes, nonalcoholic fatty liver disease) that a CMP can flag or track.

Fasting glucose, hemoglobin A1c, and a lipid panel add particular value. The Massachusetts Male Aging Study demonstrated that men with metabolic syndrome had a 2.4-fold higher risk of testosterone deficiency (Kupelian et al., JCEM 2006). A CMP also provides creatinine and eGFR, which matter for dosing decisions if a 5-alpha reductase inhibitor (finasteride or dutasteride) enters the conversation for BPH management.

For lipid monitoring during TRT, the Endocrine Society recommends assessment at baseline and 6 to 12 months after initiation, because exogenous testosterone can modestly reduce HDL cholesterol (Bhasin et al., JCEM 2018). Ordering these panels alongside PSA consolidates one blood draw into a genuinely informative snapshot.

Estradiol: The Overlooked Paired Test

Estradiol (E2) measurement is commonly neglected during TRT monitoring. Testosterone is aromatized to estradiol in adipose tissue, and elevated estradiol can cause gynecomastia, water retention, and mood disturbance. A sensitive estradiol assay (LC-MS/MS, not the standard immunoassay) is the appropriate test for men.

The target range is generally 20, 40 pg/mL in men on TRT, though the Endocrine Society has not established a formal therapeutic range for estradiol during testosterone therapy. When estradiol rises above 50 pg/mL and symptoms develop, clinicians may consider dose adjustment, switch from intramuscular to transdermal delivery (which produces less aromatization due to avoidance of first-pass adipose exposure), or in refractory cases, low-dose anastrozole.

Estradiol also has prostate relevance. Preclinical data suggest that estrogen receptor signaling in the prostate may promote inflammation and carcinogenesis through ER-alpha pathways (Ricke et al., Differentiation 2011). While this has not translated into a clinical screening recommendation for E2 as a prostate cancer marker, measuring it alongside PSA in men on TRT captures a meaningful piece of the hormonal environment.

PSA Velocity and PSA Density: Calculated, Not Ordered

PSA velocity is not a separate lab order. It is a calculation: the change in PSA over time, typically expressed as ng/mL per year. You need at least two PSA values separated by 12 to 24 months.

A velocity exceeding 0.75 ng/mL per year in the general screening population, or exceeding 1.4 ng/mL per year in men on TRT, is a trigger for urological referral (Carter et al., JAMA 2006). This is why serial PSA testing matters more than any single number.

PSA density divides total PSA by prostate volume (measured via transrectal ultrasound or MRI). A density above 0.15 ng/mL/cc is concerning, especially in the 4 to 10 ng/mL gray zone. PSA density requires imaging, so it is typically a second-line test ordered by urology after an abnormal screen. Your role in primary care or TRT management is to ensure the raw PSA data, with dates and assay consistency, is available for these calculations.

PHI and 4Kscore: When the Gray Zone Needs a Tiebreaker

The Prostate Health Index (PHI) combines total PSA, free PSA, and [-2]proPSA into a single score. The FDA approved PHI for men with total PSA between 4 and 10 ng/mL and a non-suspicious DRE. A prospective study of 658 men found PHI had an AUC of 0.72 for detecting clinically significant prostate cancer (Gleason ≥7), outperforming total PSA (AUC 0.53) and free PSA percentage (AUC 0.63) (Loeb et al., Eur Urol 2015).

The 4Kscore test combines total PSA, free PSA, intact PSA, and human kallikrein 2 (hK2) with clinical variables (age, DRE, prior biopsy status). A validation study of 1,012 men found the 4Kscore reduced unnecessary biopsies by 30 to 58% depending on the risk threshold chosen (Parekh et al., Eur Urol 2015).

These are not first-line tests. Order them when total PSA is between 4 and 10 ng/mL, free PSA ratio is ambiguous (10 to 25%), and the clinical question is "biopsy now or monitor?" Both tests are blood draws. Neither requires imaging. They are especially valuable for men on TRT whose PSA has risen modestly but predictably.

Digital Rectal Exam: Still in the Protocol

The DRE is not a lab test, but it is a paired assessment. The AUA/SUO 2023 guideline for early detection of prostate cancer recommends DRE as part of shared decision-making in men being screened with PSA. About 18% of prostate cancers are detected by DRE alone (abnormal exam with PSA <4.0 ng/mL), according to data from the PLCO trial (Andriole et al., NEJM 2009).

For TRT patients, the Endocrine Society guideline recommends a DRE at baseline and at follow-up PSA checks, though this recommendation carries a weak evidence grade. The practical reality: if you are drawing PSA, perform or arrange a DRE at the same visit. The combination catches more than either alone.

How to Lower PSA: Clinical Context, Not Supplements

PSA drops when the stimulus driving it is reduced. The two proven pharmacologic approaches are 5-alpha reductase inhibitors (5-ARIs) and treatment of underlying infection or inflammation.

Finasteride 5 mg daily reduced PSA by approximately 50% over 12 months in the Prostate Cancer Prevention Trial (N=18,882) (Thompson et al., NEJM 2003). Dutasteride 0.5 mg daily produced a similar 50 to 55% reduction in the REDUCE trial (N=6,729) (Andriole et al., NEJM 2010). The clinical rule when a patient is on a 5-ARI: double the measured PSA value to approximate the "true" PSA. If the doubled value exceeds 4.0 ng/mL, refer.

Antibiotics lower PSA when prostatitis is the cause, with reductions of 30 to 40% reported after a 4- to 6-week fluoroquinolone course in men with documented prostatic infection. There is no reliable evidence that supplements, dietary changes, or "prostate cleanses" produce clinically meaningful PSA reductions. Saw palmetto, despite widespread use, showed no effect on PSA in a randomized trial of 369 men (Barry et al., JAMA 2011).

Normal PSA by Age: Why a Single Cutoff Fails

The 4.0 ng/mL cutoff was established by consensus in the 1990s and has been under revision ever since. Age-stratified reference ranges, first proposed by Oesterling, provide better specificity:

• Ages 40, 49: 0 to 2.5 ng/mL
• Ages 50, 59: 0 to 3.5 ng/mL
• Ages 60, 69: 0 to 4.5 ng/mL
• Ages 70, 79: 0 to 6.5 ng/mL

These ranges come from a community-based study of 2,119 healthy men without prostate disease (Oesterling et al., JAMA 1993). Race-adjusted ranges have also been proposed: African American men tend to have higher PSA values at every age, and the USPSTF explicitly recommends shared decision-making starting at age 40 for men at increased risk, including African American men and those with a first-degree relative diagnosed with prostate cancer before age 65.

A man's baseline PSA at age 40, 45 is actually one of the strongest predictors of future prostate cancer risk. The Malmö Preventive Project (N=21,277, 27-year follow-up) found that men with a PSA below 1.0 ng/mL at age 44, 50 had a 0.6% risk of metastatic prostate cancer by age 75, while those with a PSA above the median had a substantially higher risk (Vickers et al., BMJ 2013). This makes a strong case for a baseline PSA draw in the early 40s as a risk-stratification tool, not a diagnostic test.

The Minimum Paired-Test Panel: A Practical Order Set

For a man presenting for prostate screening or TRT evaluation, the following single-draw panel covers the essential paired tests:

1. Total PSA
2. Free PSA (reflexed if total PSA is 2.0 to 10.0 ng/mL, or ordered upfront)
3. Total testosterone (morning fasting draw)
4. Free testosterone (calculated via SHBG, or equilibrium dialysis)
5. SHBG
6. Estradiol, sensitive (LC-MS/MS)
7. CBC with differential
8. CMP
9. Lipid panel
10. Hemoglobin A1c (if metabolic risk factors are present)

For TRT follow-up at 3 to 6 months, repeat items 1 through 9. Add hematocrit monitoring as the priority safety marker.

If PSA is in the 4 to 10 ng/mL gray zone with an ambiguous free PSA ratio (10 to 25%), order PHI or 4Kscore before proceeding to biopsy. If PSA velocity exceeds 0.75 ng/mL per year, refer to urology regardless of the absolute PSA value.